Osteoprotegerin/TNFRSF11B Antibody (155321) [Unconjugated]

HEK293 human embryonic kidney cell line transfected with Osteoprotegerin/TNFRSF11B (filled histogram) or irrelevant protein (open histogram) was stained with Mouse Anti-Human Osteoprotegerin/TNFRSF11B Monoclonal Antibody (Catalog # MAB8052) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow, CyTOF-ready
• Clone: 155321
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Osteoprotegerin/TNFRSF11B Antibody (155321) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived human Osteoprotegerin/TNFRSF11B
  Glu22-Leu401
  Accession # AAB53709.1
• Specificity: Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from ascites

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Osteoprotegerin/TNFRSF11B Antibody (155321) [Unconjugated]

• OCIF
• OCIFMGC29565
• OPG
• OPGtumor necrosis factor receptor superfamily member 11B
• Osteoclastogenesis inhibitory factor
• Osteoprotegerin
• TNFRSF11B
• TR1
• tumor necrosis factor receptor superfamily, member 11b

Background

Osteoprotegerin (OPG), also called OCIF (osteoclastogenesis inhibitory factor) is a secreted 55-60 kDa protein that regulates bone density (1-3). As a member of the tumor necrosis factor receptor (TNFR) superfamily of proteins, it is designated TNFRSF11B (1-4). Human OPG cDNA encodes 401 amino acids (aa) including a 21 aa signal peptide and a 380 aa mature soluble protein with four TNFR domains, two death domains and a heparin-binding region (4). The cysteine-rich TNFR domains are essential for ligand interaction, while a cysteine at the C-terminus mediates homodimerization (4). Mature human OPG shares 86%, 87%, 92%, 92% and 88% amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively. OPG is widely expressed and constitutively released as a homodimer by mesenchymal stem cells, fibroblasts and endothelial cells (1, 2, 5, 7). Regulation of its expression by estrogen, parathyroid hormone and cytokines is complex and changes with age (2). OPG has been called a decoy receptor for the TNF superfamily ligands, TRANCE (tumor necrosis factor-related activation-induced cytokine), also called RANK L (receptor activator of NF kappa B ligand), and TRAIL (TNF-related apoptosis-inducing ligand), which also bind TNF family receptors RANK and TRAIL receptors 1-4, respectively (2, 6). TRAIL decreases the release of OPG from cells that express it, while OPG inhibits TRAIL-induced apoptosis (5, 6). Expression of RANK L on the cell surface, and thus its ability to stimulate osteoclastogenesis, is regulated by OPG by intracellular and extracellular mechanisms (7). Within osteoblasts, interaction of the basic domain of OPG with RANK L in the Golgi inhibits RANK L secretion (7). Extracellularly, OPG binding to RANK L results in clathrin-mediated internalization and degradation of both proteins (7, 8). Binding of OPG by syndecan-1 heparin sulfates on multiple myeloma cells also results in OPG internalization and degradation, contributing to bone loss (8, 9). OPG deficiency can cause juvenile Paget’s disease in humans, and insufficient OPG to balance with RANK L and RANK can produce osteoporosis and vascular calcification in both mice and humans (2, 10, 11).

1. Simonet, W.S. et al. (1997) Cell 89:309.
2. Trouvin, A-P. and V. Goeb 2010) Clin. Interv. Aging 5:345.
3. Yasuda, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:3597.
4. Yamaguchi, K. et al. (1998) J. Biol. Chem. 273:5117.
5. Corallini, F. et al. (2010) J. Cell. Physiol. Dec. 6 [Epub ahead of print].
6. Emery, J.G. et al. (1998) J. Biol. Chem. 273:14363.
7. Aoki, S. et al. (2010) J. Bone Miner. Res. 25:1907.
8. Tat, S.K. et al. (2006) Bone 39:706.
9. Standal, T. et al. (2002) Blood 100:3002.
10. Whyte, M.P. et al. (2002) N. Engl. J. Med. 347:175.
11. Van Campenhout, A. and J. Golledge (2009) Atherosclerosis 204:321.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • AAB53709.1()